May 2026
MDMA
What May 2026's 14 new studies found, synthesized from the papers below. All MDMA research →
The synthesis
Synthesized from 13 studies in the library · AI-generated, grounded in the abstracts below
Found by searching the library for MDMA, ecstasy, molly, methylenedioxymethamphetamine, then ranked by relevance.
Research published in May 2026 indicates that MDMA-assisted therapy produces moderate-to-large reductions in psychopathology (g = 1.03) compared to controls, though with high heterogeneity and low harm-reporting quality. MDMA consistently enhances subjective social experience and reduces social threat processing, but does not reliably increase observable prosocial behavior. However, safety concerns remain, including risks of hyponatremic encephalopathy in older adults and the potential for functional unblinding in trials, and evidence on long-term effects is limited.
Evidence by study
Direction is which way each study's own result points, not our rating of the study. All 14 matching studies were reviewed; the 13 that directly address the question are shown here.
What the directions mean
- Supports:
- the study found the intervention worked, or its hypothesis held.
- Opposes:
- it found the opposite, no benefit or a harm.
- No effect:
- no significant difference either way.
- Mixed:
- effects in both directions within the same study.
- Unclear:
- the abstract does not report a direction.
| Study | Design | Sample size | Direction | Finding |
|---|---|---|---|---|
| Antibiotic-induced Microbiome Depletion Selectively Reduces Baseline Hypothalamic Oxytocin Signaling without Affecting MDMA-induced Oxytocin Response in Rats. 2026 | randomized controlled trial | No effect | Antibiotic-induced microbiome depletion reduced baseline central oxytocin expression but did not alter MDMA-induced oxytocin responses in the brain or circulation. | |
| Blinding integrity in psychedelic research: Evidence from a comparative randomized controlled trial of psilocybin, MDMA, and methylphenidate in healthy volunteers. 2026 | randomized controlled trial | 120 | Mixed | Blinding was insufficient overall, with psilocybin showing the highest functional unblinding, MDMA moderate, and methylphenidate the lowest, indicating that MDMA's effects are distinguishable from placebo. |
| The Serotonin 2B (5‐ HT2B ) Receptor: A Narrative Review of Preclinical and Clinical Evidence on the Safety Considerations and Therapeutic Potential for the Treatment of Depression 2026 | narrative review | Unclear | The review argues that peripheral 5-HT2B receptor agonism is linked to valvular heart disease, with supportive but limited data for MDMA, while central 5-HT2B antagonism may be a therapeutic target for depression. | |
| Differential alterations in peripheral tryptophan pathways in methamphetamine versus MDMA users are linked to their contrasting psychiatric symptoms. 2026 | cross-sectional study | 140 | Mixed | Chronic MDMA use was associated with selective activation of the OH-kynurenine metabolic branch, whereas chronic METH use was linked to depletion of tryptophan and serotonin and general kynurenine pathway activation, with metabolite changes related to psychiatric symptoms. |
| Reply: The consequences of MDMA use are not easily disentangled from other drug use or lifestyle factors. 2026 | reply | Unclear | The authors argue that the consequences of MDMA use are not easily disentangled from other drug use or lifestyle factors. | |
| Psychedelic Use and Missed Needed Mental Health Treatment: Gender Differences in Unmet Perceived Need for Care 2026 | observational cohort | Mixed | Psychedelic use was not independently associated with lower odds of missing needed mental health treatment, but it moderated the distress–missed care relationship, with MDMA showing a buffering effect in women and psychedelics in men. | |
| Development of the MDMA-Assisted Psychotherapy Side Effects Tool (M-SET): a Delphi study. 2026 | tool development with modified Delphi process | 12 | Unclear | A structured 165-item tool (M-SET) was developed through expert consensus to systematically assess side effects of MDMA-assisted psychotherapy. |
| Glutathione as a Potential Neuroprotectant Against MDMA-Induced Oxidative Stress, Neuroinflammation, and Apoptosis in the Rat Brain. 2026 | randomized controlled trial | 60 | Mixed | Glutathione partially protected against MDMA-induced neurotoxicity at moderate doses but was less effective at high doses. |
| R-MDDMA is a Safer Analogue of MDMA with Therapeutic Potential. 2026 | preclinical study | Supports | R-MDDMA promoted neuroplasticity, fear extinction learning, and antidepressant-like effects without the abuse-related effects of MDMA. | |
| MDMA-Assisted Therapy Randomized Controlled Trial Incremental Effects Systematic Review and Meta-Analysis 2026 | systematic review and meta-analysis | 295 | Supports | MDMA-AT demonstrated a significant moderate-to-large incremental reduction in psychopathology relative to controls (g = 1.03, 95% CI [0.46, 1.60]), but heterogeneity was high and harm reporting quality was low. |
| Prevalence and Reasons for Microdosing Cannabis, Psilocybin, LSD, and MDMA Among U.S. Adults 2026 | cross-sectional survey | 1523 | Unclear | MDMA was microdosed by 2.2% of U.S. adults, primarily for recreational purposes, and microdosing was more common among those with poorer mental health. |
| A Systematic Review of MDMA’s Effects on Social Functioning in Placebo-Controlled Trials 2026 | systematic review | 76 | Mixed | MDMA consistently enhanced subjective social experience and reduced social threat processing, but did not reliably enhance observable prosocial behavior. |
| Severe Hyponatremic Encephalopathy Induced by Unsupervised "Therapeutic" 3,4-Methylenedioxymethamphetamine Use in a 55-Year-Old Woman: A Diagnostic Pitfall. 2026 | case report | 1 | Opposes | MDMA-induced hyponatremic encephalopathy occurred in an older adult in a non-recreational setting, highlighting a diagnostic pitfall due to representativeness bias. |
Antibiotic-induced microbiome depletion reduced baseline central oxytocin expression but did not alter MDMA-induced oxytocin responses in the brain or circulation.
randomized controlled trial
Blinding was insufficient overall, with psilocybin showing the highest functional unblinding, MDMA moderate, and methylphenidate the lowest, indicating that MDMA's effects are distinguishable from placebo.
randomized controlled trial Sample size: 120
The review argues that peripheral 5-HT2B receptor agonism is linked to valvular heart disease, with supportive but limited data for MDMA, while central 5-HT2B antagonism may be a therapeutic target for depression.
narrative review
Chronic MDMA use was associated with selective activation of the OH-kynurenine metabolic branch, whereas chronic METH use was linked to depletion of tryptophan and serotonin and general kynurenine pathway activation, with metabolite changes related to psychiatric symptoms.
cross-sectional study Sample size: 140
The authors argue that the consequences of MDMA use are not easily disentangled from other drug use or lifestyle factors.
reply
Psychedelic use was not independently associated with lower odds of missing needed mental health treatment, but it moderated the distress–missed care relationship, with MDMA showing a buffering effect in women and psychedelics in men.
observational cohort
A structured 165-item tool (M-SET) was developed through expert consensus to systematically assess side effects of MDMA-assisted psychotherapy.
tool development with modified Delphi process Sample size: 12
Glutathione partially protected against MDMA-induced neurotoxicity at moderate doses but was less effective at high doses.
randomized controlled trial Sample size: 60
R-MDDMA promoted neuroplasticity, fear extinction learning, and antidepressant-like effects without the abuse-related effects of MDMA.
preclinical study
MDMA-AT demonstrated a significant moderate-to-large incremental reduction in psychopathology relative to controls (g = 1.03, 95% CI [0.46, 1.60]), but heterogeneity was high and harm reporting quality was low.
systematic review and meta-analysis Sample size: 295
MDMA was microdosed by 2.2% of U.S. adults, primarily for recreational purposes, and microdosing was more common among those with poorer mental health.
cross-sectional survey Sample size: 1523
MDMA consistently enhanced subjective social experience and reduced social threat processing, but did not reliably enhance observable prosocial behavior.
systematic review Sample size: 76
MDMA-induced hyponatremic encephalopathy occurred in an older adult in a non-recreational setting, highlighting a diagnostic pitfall due to representativeness bias.
case report Sample size: 1
Points of agreement
- MDMA consistently alters subjective social experience and reduces social threat processing.
- MDMA-assisted therapy shows significant reductions in psychopathology, though with high heterogeneity.
- MDMA's effects are distinguishable from placebo, leading to functional unblinding in trials.
- MDMA use is associated with potential safety risks, including neurotoxicity and hyponatremia.
Conflicts
- MDMA-assisted therapy shows large effects in meta-analysis, but harm reporting quality is low and heterogeneity is high.
- MDMA enhances subjective prosocial feelings but does not reliably increase observable prosocial behavior.
- Chronic MDMA use is linked to selective kynurenine pathway activation, but the clinical implications are unclear and may be confounded by other drug use.
Gaps
- Long-term durability of MDMA-assisted therapy effects is not addressed.
- Blinding integrity is insufficient, and methods to improve blinding are needed.
- Safety data on MDMA in older adults and non-recreational settings are limited.
- The therapeutic potential of MDMA analogues like R-MDDMA requires further clinical validation.
- The impact of microbiome depletion on MDMA effects in humans is unknown.